A Rapid Systematic Review of U.S. Food and Drug Administration–authorized COVID-19 Treatments - Top-Institutions - MDSpire

A Rapid Systematic Review of U.S. Food and Drug Administration–authorized COVID-19 Treatments

  • By

  • David J Sullivan

  • Massimo Franchini

  • Michael J Joyner

  • Arturo Casadevall

  • Daniele Focosi

  • October 9, 2025

  • 0 min

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    National Institutes of Health (NIH)
    National Institutes of Health (NIH)

    Bethesda, MD

    Key Differentiators

    • Infectious Diseases
    • Clinical Trials
    • Immunology

  • #2

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Infectious Diseases
    • Epidemiology
    • Clinical Research

  • #3

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Hematology
    • Infectious Diseases
    • Clinical Trials

  • #4

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Infectious Diseases
    • Clinical Pharmacology
    • Epidemiology

  • #5

    Massachusetts General Hospital (MGH)
    Massachusetts General Hospital (MGH)

    Boston, MA

    Key Differentiators

    • Infectious Diseases
    • Critical Care Medicine
    • Clinical Trials

Original Source(s)

A Rapid Systematic Review of U.S. Food and Drug Administration–authorized COVID-19 Treatments

  • by David J Sullivan, Massimo Franchini, Michael J Joyner, Arturo Casadevall, Daniele Focosi

  • October 9, 2025

Related Content

Human Papillomavirus Vaccine Discourse and Sentiment on Reddit Before and After COVID-19: Mixed Methods Retrospective Cross-Sectional Study

Post-acute metabolic changes and risk of new-onset diabetes following COVID-19: a systematic review and meta-analysis

Increased anti-nucleocapsid secretory IgA and consumption of complement component 3 in post-COVID syndrome patients